169 related articles for article (PubMed ID: 17664326)
1. Enhancement of apoptosis of THP-1 cells infected with Mycobacterium tuberculosis by inhalable microparticles and relevance to bactericidal activity.
Yadav AB; Misra A
Antimicrob Agents Chemother; 2007 Oct; 51(10):3740-2. PubMed ID: 17664326
[TBL] [Abstract][Full Text] [Related]
2. Inhalable microparticles containing isoniazid and rifabutin target macrophages and 'stimulate the phagocyte' to achieve high efficacy.
Yadav AB; Sharma R; Muttil P; Singh AK; Verma RK; Mohan M; Patel SK; Misra A
Indian J Exp Biol; 2009 Jun; 47(6):469-74. PubMed ID: 19634713
[TBL] [Abstract][Full Text] [Related]
3. Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill Mycobacterium tuberculosis.
Verma RK; Agrawal AK; Singh AK; Mohan M; Gupta A; Gupta P; Gupta UD; Misra A
Tuberculosis (Edinb); 2013 Jul; 93(4):412-7. PubMed ID: 23562366
[TBL] [Abstract][Full Text] [Related]
4. Inhalable locust bean gum microparticles co-associating isoniazid and rifabutin: Therapeutic assessment in a murine model of tuberculosis infection.
Grenha A; Alves AD; Guerreiro F; Pinho J; Simões S; Almeida AJ; Gaspar MM
Eur J Pharm Biopharm; 2020 Feb; 147():38-44. PubMed ID: 31790800
[TBL] [Abstract][Full Text] [Related]
5. Drugs for tuberculosis.
Treat Guidel Med Lett; 2004 Dec; 2(28):83-8. PubMed ID: 15557876
[No Abstract] [Full Text] [Related]
6. Inhalable microparticles containing large payload of anti-tuberculosis drugs.
Muttil P; Kaur J; Kumar K; Yadav AB; Sharma R; Misra A
Eur J Pharm Sci; 2007 Oct; 32(2):140-50. PubMed ID: 17681458
[TBL] [Abstract][Full Text] [Related]
7. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
8. Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra.
Sharma R; Muttil P; Yadav AB; Rath SK; Bajpai VK; Mani U; Misra A
J Antimicrob Chemother; 2007 Mar; 59(3):499-506. PubMed ID: 17242031
[TBL] [Abstract][Full Text] [Related]
9. Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice.
Verma RK; Kaur J; Kumar K; Yadav AB; Misra A
Antimicrob Agents Chemother; 2008 Sep; 52(9):3195-201. PubMed ID: 18591268
[TBL] [Abstract][Full Text] [Related]
10. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein.
Hartkoorn RC; Chandler B; Owen A; Ward SA; Bertel Squire S; Back DJ; Khoo SH
Tuberculosis (Edinb); 2007 May; 87(3):248-55. PubMed ID: 17258938
[TBL] [Abstract][Full Text] [Related]
11. The receptor-mediated uptake, survival, replication, and drug sensitivity of Mycobacterium tuberculosis within the macrophage-like cell line THP-1: a comparison with human monocyte-derived macrophages.
Stokes RW; Doxsee D
Cell Immunol; 1999 Oct; 197(1):1-9. PubMed ID: 10555990
[TBL] [Abstract][Full Text] [Related]
12. HLA-DRB1*1501 and VDR polymorphisms and survival of Mycobacterium tuberculosis in human macrophages exposed to inhalable microparticles.
Singh AK; Abhimanyu ; Yadav AB; Sharma S; Garg R; Bose M; Misra A
Pharmacogenomics; 2013 Apr; 14(5):531-40. PubMed ID: 23556450
[TBL] [Abstract][Full Text] [Related]
13. Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis.
Lounis N; Maslo C; Truffot-Pernot C; Grosset J; Boelaert RJ
Int J Tuberc Lung Dis; 2003 Jun; 7(6):575-9. PubMed ID: 12797701
[TBL] [Abstract][Full Text] [Related]
14. Isoniazid activity is terminated by bacterial persistence.
Mitchison DA; Jindani A; Davies GR; Sirgel F
J Infect Dis; 2007 Jun; 195(12):1871-2; author reply 1872-3. PubMed ID: 17492605
[No Abstract] [Full Text] [Related]
15. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
Jenny-Avital ER; Joseph K
Clin Infect Dis; 2009 May; 48(10):1471-4. PubMed ID: 19368504
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
Pandey R; Khuller GK
J Antimicrob Chemother; 2004 Jul; 54(1):266-8. PubMed ID: 15128731
[TBL] [Abstract][Full Text] [Related]
17. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig.
Ahmad Z; Klinkenberg LG; Pinn ML; Fraig MM; Peloquin CA; Bishai WR; Nuermberger EL; Grosset JH; Karakousis PC
J Infect Dis; 2009 Oct; 200(7):1136-43. PubMed ID: 19686043
[TBL] [Abstract][Full Text] [Related]
18. Inhalable chitosan microparticles for simultaneous delivery of isoniazid and rifabutin in lung tuberculosis treatment.
Cunha L; Rodrigues S; Rosa da Costa AM; Faleiro L; Buttini F; Grenha A
Drug Dev Ind Pharm; 2019 Aug; 45(8):1313-1320. PubMed ID: 30990096
[TBL] [Abstract][Full Text] [Related]
19. [Complex research studies in the testing of the effectiveness of phenaside].
Sel'tsovskiĭ PP; Irtuganova OA; Slogotskaia LV; Smirnova NS; Moroz AM; Borzenko AS; Spasov AA; Smirnova LA; Dzhura PI; Karpov AV; Ivanovskiĭ VB; Pauker MN; Plemiannikova GI
Probl Tuberk; 2001; (8):29-31. PubMed ID: 11767386
[No Abstract] [Full Text] [Related]
20. Spray-dried fucoidan microparticles for pulmonary delivery of antitubercular drugs.
Cunha L; Rosa da Costa AM; Lourenço JP; Buttini F; Grenha A
J Microencapsul; 2018 Jun; 35(4):392-405. PubMed ID: 30112917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
